The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Oncotarget, 7, 27, S. 41233-41241
- Event
-
Veröffentlichung
- (where)
-
Augsburg
- (who)
-
Universität Augsburg
- (when)
-
2016
- Event
-
Veröffentlichung
- (who)
-
Impact Journals, LLC
- (when)
-
2016
- Creator
-
Wolf, Herta
Beykan, Seval
Higuchi, Takahiro
Lückerath, Katharina
Weich, Alexander
Scheurlen, Michael
Bluemel, Christina
Herrmann, Ken
Buck, Andreas K.
Lassmann, Michael
Lapa, Constantin Frederik Victor
Hänscheid, Heribert
- DOI
-
10.18632/oncotarget.9775
- URN
-
urn:nbn:de:bvb:384-opus4-633758
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wolf, Herta
- Beykan, Seval
- Higuchi, Takahiro
- Lückerath, Katharina
- Weich, Alexander
- Scheurlen, Michael
- Bluemel, Christina
- Herrmann, Ken
- Buck, Andreas K.
- Lassmann, Michael
- Lapa, Constantin Frederik Victor
- Hänscheid, Heribert
- Universität Augsburg
- Impact Journals, LLC
Time of origin
- 2016
Other Objects (12)
68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs
Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie
Freehand SPECT-guided sentinel lymph node biopsy in early oral squamous cell carcinoma
OP240 Incidence of hyperkalemia in patients undergoing radiopeptide therapy does not depend on the amount of co-infused amino acid infusion [Abstract]
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms
Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom
68Ga-Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in neuroendocrine tumors: a head-to-head comparison with DOTATOC and FDG PET/CT [Abstract]
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted?
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Paralytic subileus as an adverse effect of amino acid–based nephroprotection in a patient undergoing peptide receptor radionuclide therapy
68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs
Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie
Freehand SPECT-guided sentinel lymph node biopsy in early oral squamous cell carcinoma
OP240 Incidence of hyperkalemia in patients undergoing radiopeptide therapy does not depend on the amount of co-infused amino acid infusion [Abstract]
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms
Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom
68Ga-Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in neuroendocrine tumors: a head-to-head comparison with DOTATOC and FDG PET/CT [Abstract]
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted?
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
Paralytic subileus as an adverse effect of amino acid–based nephroprotection in a patient undergoing peptide receptor radionuclide therapy
68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs
Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie
Freehand SPECT-guided sentinel lymph node biopsy in early oral squamous cell carcinoma
OP240 Incidence of hyperkalemia in patients undergoing radiopeptide therapy does not depend on the amount of co-infused amino acid infusion [Abstract]
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptoms
Lenvatinib : Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom
68Ga-Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in neuroendocrine tumors: a head-to-head comparison with DOTATOC and FDG PET/CT [Abstract]
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
Pretherapeutic estimation of kidney function in patients treated with peptide receptor radionuclide therapy: can renal scintigraphy be safely omitted?
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy